Latanoprostene bunod: Phase I started

Bausch + Lomb began the open-label, Japanese Phase I KRONUS trial to evaluate once-daily 0.024% latanoprostene bunod for 14 days in about 24 healthy male volunteers. Bausch + Lomb has exclusive, world...